(Q33671891)

English

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis (English)

1 reference

Europe PubMed Central

28 July 2017

0 references

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kathleen N Moore

1

1 reference

Europe PubMed Central

28 July 2017

Chunqiao Tian

2

1 reference

Europe PubMed Central

28 July 2017

D Scott McMeekin

3

1 reference

Europe PubMed Central

28 July 2017

J Tate Thigpen

4

1 reference

Europe PubMed Central

28 July 2017

Marcus E Randall

5

1 reference

Europe PubMed Central

28 July 2017

Holly H Gallion

6

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

24 August 2010

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

116

1 reference

Europe PubMed Central

28 July 2017

23

1 reference

Europe PubMed Central

28 July 2017

5407-5414

1 reference

Europe PubMed Central

28 July 2017

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

21 January 2018

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25480

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25480

1 reference

Europe PubMed Central

28 July 2017

OpenCitations bibliographic resource ID

0 references

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33671891&oldid=1805689163"